Spots Global Cancer Trial Database for vosaroxin
Every month we try and update this database with for vosaroxin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | NCT03338348 | Acute Myeloid L... Myelodysplastic... | Vosaroxin Azacitidine | 60 Years - | University of Ulm | |
| Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia | NCT00607997 | Leukemia Acute Disease Acute Myeloid L... Nonlymphocytic ... Myelodysplastic... | vosaroxin | 60 Years - | Sunesis Pharmaceuticals | |
| Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy | NCT01980056 | Myelodysplastic... | Vosaroxin | 18 Years - | Weill Medical College of Cornell University | |
| Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies | NCT00246662 | Leukemia, Lymph... Leukemia, Nonly... Leukemia, Myelo... Myelodysplastic... | Vosaroxin | 18 Years - | Sunesis Pharmaceuticals | |
| Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes | NCT01913951 | Myelodysplastic... | vosaroxin Azacitidine | 18 Years - | Washington University School of Medicine | |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML | NCT02485353 | Leukemia, Myelo... | Vosaroxin and C... | 60 Years - | Indiana University | |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia | NCT02658487 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Myeloid Sarcoma Secondary Acute... Therapy-Related... Therapy-Related... | Cytarabine Vosaroxin | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | NCT01893320 | Leukemia | Vosaroxin Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | NCT02416388 | Acute Myeloid L... | Idarubicin Daunorubicin HD Cytarabine Cyclosporine Methotrexate Mycophenolic ac... vosaroxin ID cytarabine Dexamethasone Venetoclax | 18 Years - 61 Years | University Hospital, Angers |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
